Medical researchers with EDP Biotech Corporation (EDP) have captured national attention with their revolutionary new technology for a simple blood test to detect early-stage colon cancer.
Following the success of its pre-clinical trials for the ColoMarker(TM) assay, EDP has filed a patent on the biomarker, CA11-19, and all aspects of its use. Via an inexpensive blood test, ColoMarker(TM) will detect colon cancer in its earliest, most curable stages.
"American Cancer Society statistics show that when colon cancer is detected in its early stages, more than 90% of patients will survive. If not detected until the later stages, fewer than 10% will survive. ColoMarker(TM) detects colon cancer in these early, highly curable stages," says Kevin Jones, Ph.D., Chief Scientific Officer of EDP.
According to American Cancer Society statistics, fewer than 20% of Americans over the age of 50 who should be screened for colon cancer, actually are. With the use of ColoMarker(TM), a simple and inexpensive blood test, the number of people being screened would likely increase dramatically, leading to a decline in deaths due to colon cancer.
In pre-clinical trials, ColoMarker(TM) successfully detected the early stages (I, II, and III) of colon cancer. In tests of 2,370 blood samples, ColoMarker(TM) showed an accuracy rate of >99% for detecting colon cancer in these early stages. "ColoMarker(TM) could lead to a radical shift in the way we detect colon cancer," adds Dr. Jones.
National researchers who study colorectal cancer are closely monitoring emerging technologies such as ColoMarker(TM). Their findings are encouraging; just last week, the American Cancer Society, the National Cancer Institute, the Centers for Disease Control and Prevention and the North American Association of Central Cancer Registries released an optimistic report about the expected decline in deaths from colon cancer due to anticipated improvements in early screening methods.
Dr. Jones states, "The use of ColoMarker(TM) as a screening test could save tens of thousands of American lives every year and billions of dollars in healthcare costs." EDP Biotech is now moving forward expeditiously to get ColoMarker(TM) through the Food and Drug Administration clearance process.
About EDP Biotech Corporation
EDP Biotech Corporation (EDP) is a medical device company focused on the development and sale of immunodiagnostic tests for both humans and animals. EDP utilizes more than 30 years of research and development in identification and purification of proteins present in the early stages of biological changes for production of in vitro diagnostic tests whose primary target is Early Detection Products.
Source: EDP Biotech Corporation
суббота, 2 июля 2011 г.
пятница, 1 июля 2011 г.
St. Jude Medical Announces U.S. Launch Of TigerWire Steerable Guidewire
St. Jude Medical, Inc. (NYSE:STJ) announced U.S. launch of the TigerWire(TM) Steerable Guidewire. The newest member of the St. Jude Medical GuideRight(TM) family of steerable guidewires, the TigerWire Steerable Guidewire is designed to enhance physicians' ability to steer through challenging peripheral arteries, the vessels that supply blood to the legs and arms.
A guidewire is a thin, flexible wire that physicians use to help guide and steer a catheter (a flexible tube) through the arteries. Catheters are used to assist in diagnosing and treating blockages caused by a build-up of plaque inside artery walls. Plaque build-up can block blood flow and lead to heart attack or stroke.
The TigerWire Guidewire's tip is designed with enhanced flexibility to aid in navigation through the vessels. Its supportive design provides distinct zones of flexibility that make it easier for physicians to track and position the guidewire through challenging anatomy.
"The TigerWire Steerable Guidewire has been engineered for improved steerability," said Frank Callaghan, president of the St. Jude Medical Cardiovascular Division. "It gives physicians a tool that can ease access to difficult-to-reach vessels when performing complex diagnostic and interventional procedures."
The insertion of a guidewire is a first step in interventional procedures in which physicians thread catheters through the arteries to diagnose the severity of disease or deliver treatments, including devices such as stents that open blockages and restore blood flow.
Each year, an estimated 4 million cardiovascular catheterization procedures are performed in the U.S., according to IMV, a research and publishing firm specializing in the medical imaging and clinical diagnostic instruments markets.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 12,000 people worldwide. For more information, please visit sjm.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings, and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's Annual Report on Form 10-K filed on February 27, 2008 (see Item 1A on pages 13-20, and page 20 of Exhibit 13 to the Company's Form 10-K). The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
St. Jude Medical
A guidewire is a thin, flexible wire that physicians use to help guide and steer a catheter (a flexible tube) through the arteries. Catheters are used to assist in diagnosing and treating blockages caused by a build-up of plaque inside artery walls. Plaque build-up can block blood flow and lead to heart attack or stroke.
The TigerWire Guidewire's tip is designed with enhanced flexibility to aid in navigation through the vessels. Its supportive design provides distinct zones of flexibility that make it easier for physicians to track and position the guidewire through challenging anatomy.
"The TigerWire Steerable Guidewire has been engineered for improved steerability," said Frank Callaghan, president of the St. Jude Medical Cardiovascular Division. "It gives physicians a tool that can ease access to difficult-to-reach vessels when performing complex diagnostic and interventional procedures."
The insertion of a guidewire is a first step in interventional procedures in which physicians thread catheters through the arteries to diagnose the severity of disease or deliver treatments, including devices such as stents that open blockages and restore blood flow.
Each year, an estimated 4 million cardiovascular catheterization procedures are performed in the U.S., according to IMV, a research and publishing firm specializing in the medical imaging and clinical diagnostic instruments markets.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 12,000 people worldwide. For more information, please visit sjm.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings, and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's Annual Report on Form 10-K filed on February 27, 2008 (see Item 1A on pages 13-20, and page 20 of Exhibit 13 to the Company's Form 10-K). The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
St. Jude Medical
четверг, 30 июня 2011 г.
MOM, Metal Ions And Lymphopenia
Metal-on-metal hip replacement and resurfacing have become the most commonly used type of procedure in the United Kingdom for patients who are < 60 years of age with osteoarthritis. Therefore, this research consisted of a cross-sectional study with analysis of demographic, clinical and laboratory characteristics of patients who had undergone metal-on-metal hip resurfacing, ceramic-on-ceramic and metal-on-polyethylene hip replacement to assess whether there was a relationship between MOM replacements and circulating metal ions in the blood, and absolute numbers of circulating lymphocytes.
There were 164 patients in the study, of which 106 had MOM hips, all were aged < 65 years and had pre-operative diagnosis of osteoarthritis and no pre-existing immunological disorders. Patients were excluded if their replacement had taken place less than six months previously, thereby avoiding the high-wearing, bedding-in phase. Blood samples were taken using a plastic needle cannula to avoid metal contamination.
The results showed that 'there were significant differences in the levels of metal ions in the whole blood and in the absolute lymphocyte counts'. A group of 10 patients of the 106 from the MOM group had circulating levels of chromium greater than 5 parts per billion. Therefore, the authors conclude that 'patients with MOM hips had reduced peripheral blood counts of T-lymphocytes in particular and B-lymphocytes when compared with control subjects with hip replacements which did not produce metal wear debris'. Although the effect of reduced lymphocytes is unknown, there has been a link between high levels of cobalt and chromium and DNA damage of lymphocytes and the authors recommend that long-term studies need to be conducted to determine whether the moderate lymphopenia associated with MOM hip replacements is detrimental or even beneficial to longevity of the replacement.
Read the full text article.
Source
The Journal of Bone and Joint Surgery
There were 164 patients in the study, of which 106 had MOM hips, all were aged < 65 years and had pre-operative diagnosis of osteoarthritis and no pre-existing immunological disorders. Patients were excluded if their replacement had taken place less than six months previously, thereby avoiding the high-wearing, bedding-in phase. Blood samples were taken using a plastic needle cannula to avoid metal contamination.
The results showed that 'there were significant differences in the levels of metal ions in the whole blood and in the absolute lymphocyte counts'. A group of 10 patients of the 106 from the MOM group had circulating levels of chromium greater than 5 parts per billion. Therefore, the authors conclude that 'patients with MOM hips had reduced peripheral blood counts of T-lymphocytes in particular and B-lymphocytes when compared with control subjects with hip replacements which did not produce metal wear debris'. Although the effect of reduced lymphocytes is unknown, there has been a link between high levels of cobalt and chromium and DNA damage of lymphocytes and the authors recommend that long-term studies need to be conducted to determine whether the moderate lymphopenia associated with MOM hip replacements is detrimental or even beneficial to longevity of the replacement.
Read the full text article.
Source
The Journal of Bone and Joint Surgery
среда, 29 июня 2011 г.
New Vascular Channel On
is pleased to announce the launch of a new Vascular channel. The section will include news on arterial diseases (aortic abdominal aneurysms, thoracic aortic aneurysms, aortic arch, dissections and ischemia, as well as peripheral arterial disease) and venous diseases (varicose veins and deep vein thrombosis).
asks that any subscribers to the tailored Newsletter or Newsalert, who would like to receive the news from this new section in their e-mails, amend their preferences using the link provided in their last/next e-mail from (or use our feedback form if you would like assistance).
Other channels that have been added recently and will also need to be updated in the e-mail subscriptions include:
Asbestos / Mesothelioma
Back Pain
COPD
Eczema / Psoriasis
Fibromyalgia
Lymphology/Lymphedema
Medical Practice Management
Melanoma / Skin Cancer
Menopause
Ovarian Cancer
Palliative Care / Hospice Care
Tuberculosis
Veterans / Ex-Servicemen
If you have a suggestion for another new channel you would like to see on our site please fill in the form at the bottom of our Contact Us page.
To sign up for one of our free e-mails please fill in the form on the relevant page:
Weekly Newsletter
Daily Newsalert
Every e-mail provides you with a link to unsubscribe or change your preferences if you wish to do so.
asks that any subscribers to the tailored Newsletter or Newsalert, who would like to receive the news from this new section in their e-mails, amend their preferences using the link provided in their last/next e-mail from (or use our feedback form if you would like assistance).
Other channels that have been added recently and will also need to be updated in the e-mail subscriptions include:
Asbestos / Mesothelioma
Back Pain
COPD
Eczema / Psoriasis
Fibromyalgia
Lymphology/Lymphedema
Medical Practice Management
Melanoma / Skin Cancer
Menopause
Ovarian Cancer
Palliative Care / Hospice Care
Tuberculosis
Veterans / Ex-Servicemen
If you have a suggestion for another new channel you would like to see on our site please fill in the form at the bottom of our Contact Us page.
To sign up for one of our free e-mails please fill in the form on the relevant page:
Weekly Newsletter
Daily Newsalert
Every e-mail provides you with a link to unsubscribe or change your preferences if you wish to do so.
вторник, 28 июня 2011 г.
2010 Merit Award Winners Announced By ASH
The American Society of Hematology (ASH) recognizes the following abstract presenters at the 52nd ASH Annual Meeting in Orlando, FL, with the highest scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and post-doctoral fellow. Merit Award winners receive a $500 honorarium plus annual meeting travel reimbursement.
The 2010 Merit Award recipients are:
Undergraduate Student
Maria Virgilio
Treatment of Zebrafish Models of Ribosomopathies (Diamond Blackfan Anemia (DBA) and 5q- Syndrome) With L-Leucine Results in an Improvement of Anemia and Developmental Defects: Evidence for a Common Pathway?
Abstract #195
Medical Student
Karrune Woan
Identification of a Discrete Subpopulation of T-Cells Over-Expressing HDAC11 With a TH17 Phenotype
Abstract #588
Graduate Student
Wulan Deng
Manipulating Higher Order Chromatin Structure of the ОІ-Globin Locus by Targeted Tethering of a "Looping" Factor
Abstract #647
Post-Doctoral Fellow
Jian Xu, PhD
Reactivation of Silenced Human HbF in Adult Mice by Inactivation of BCL11A
Abstract #643
Mary Rodes Gibson Memorial Award in Hemostasis and Thrombosis
This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest scoring abstract submitted in the field of hemostasis and thrombosis. This annual award is made possible by the Mary Rodes Gibson Hemostasis-Thrombosis Foundation to continue the legacy of Mary Rodes Gibson, who suffered from severe, type 3 von Willebrand disease.
The 2010 recipient is:
Louisa M. Dowal, PhD
A Chemical Genetic Analysis of Platelet Activation Identifies an Antithrombotic Allosteric Modulator That Acts Through Helix 8 of Par1
Abstract #483
Source:
Lindsey Love
American Society of Hematology
The 2010 Merit Award recipients are:
Undergraduate Student
Maria Virgilio
Treatment of Zebrafish Models of Ribosomopathies (Diamond Blackfan Anemia (DBA) and 5q- Syndrome) With L-Leucine Results in an Improvement of Anemia and Developmental Defects: Evidence for a Common Pathway?
Abstract #195
Medical Student
Karrune Woan
Identification of a Discrete Subpopulation of T-Cells Over-Expressing HDAC11 With a TH17 Phenotype
Abstract #588
Graduate Student
Wulan Deng
Manipulating Higher Order Chromatin Structure of the ОІ-Globin Locus by Targeted Tethering of a "Looping" Factor
Abstract #647
Post-Doctoral Fellow
Jian Xu, PhD
Reactivation of Silenced Human HbF in Adult Mice by Inactivation of BCL11A
Abstract #643
Mary Rodes Gibson Memorial Award in Hemostasis and Thrombosis
This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest scoring abstract submitted in the field of hemostasis and thrombosis. This annual award is made possible by the Mary Rodes Gibson Hemostasis-Thrombosis Foundation to continue the legacy of Mary Rodes Gibson, who suffered from severe, type 3 von Willebrand disease.
The 2010 recipient is:
Louisa M. Dowal, PhD
A Chemical Genetic Analysis of Platelet Activation Identifies an Antithrombotic Allosteric Modulator That Acts Through Helix 8 of Par1
Abstract #483
Source:
Lindsey Love
American Society of Hematology
понедельник, 27 июня 2011 г.
Racial Differences In Risk Factors For Venous Thromboembolism And Pulmonary Embolism
A new study of 1,960 White-Americans and 368 Black-Americans with objectively diagnosed venous thromboembolism (VTE) showed that, compared to Whites, Blacks had a significantly higher proportion with pulmonary embolism (PE), including idiopathic PE among Black women, and a significantly higher proportion of Blacks with VTE were women (71% vs 61% for Whites) The study is published in the American Journal of Hematology.
VTE is blood clots in veins and consists of deep vein thrombosis (DVT), a blood clot in the "inner" or "deep" vein, typically of the leg or pelvis, and its complication, PE, a dislodged DVT that has traveled with the returning blood to the heart and become lodged in the lungs. Most epidemiologic studies of VTE risk factors have been conducted within White-American and -European populations. However, compared to Whites, Black-Americans appear to have a higher risk and incidence of VTE. Two single nucleotide polymorphisms (DNA sequence variations), factor V Leiden (G1691A) and prothrombin (G20210A), have been identified as risk factors for DVT and PE in Europeans and White-Americans, but not Black- Americans.
"VTE appears to be more common in Blacks than Whites, but while we have identified many inherited causes for VTE in Whites, no such inherited causes in Blacks have been identified," said lead researcher Prof. John Heit, of the Mayo Clinic College of Medicine, Minnesota, USA. "We wondered whether Blacks were more likely to have VTE related to common exposures that can cause VTE, such as major surgery, hospitalization for acute medical illness, trauma, fracture, or birth control pills, to account for VTE being more common in Blacks, but this does not appear to be the case. Thus, we now question whether Blacks may have some as yet unidentified inherited cause for VTE."
The researchers found that, compared to Whites with VTE, Blacks with VTE have a higher proportion of PE events, a lower proportion of VTE related to transient risk factors and a higher proportion with idiopathic VTE, i.e. from a seemingly unknown or unrelated cause.
Blacks had a significantly higher mean BMI, and a significantly lower proportion with recent surgery, trauma or infection, family history of VTE and documented thrombophilia. Conversely, Blacks had a significantly higher proportion with hypertension, diabetes mellitus, chronic renal disease and dialysis, HIV and sickle cell disease. Compared to White women, Black women had a significantly lower proportion with recent oral contraceptive use or hormone therapy
"Given the poor survival after PE, our finding of an increased prevalence of PE among Blacks (particularly idiopathic PE) is disturbing, especially when coupled with previous reports of increased complications after VTE and higher PE case-fatality among Blacks," added Heit.
The study is accompanied by an editorial by Dr. Samuel Goldhaber of Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
Full citation:
JA Heit et al; Comparison of Characteristics from White- and Black-Americans with Venous Thromboembolism: A Cross Sectional Study; American Journal of Hematology, 2010; DOI: 10.1002/ajh.21735
About the author:
John A. Heit, M.D., FACP, FACC, is Director of Coagulation Laboratories and Professor of Medicine at the Mayo Clinic College of Medicine, MN, USA.
Source:
Amy Molnar
Wiley-Blackwell
VTE is blood clots in veins and consists of deep vein thrombosis (DVT), a blood clot in the "inner" or "deep" vein, typically of the leg or pelvis, and its complication, PE, a dislodged DVT that has traveled with the returning blood to the heart and become lodged in the lungs. Most epidemiologic studies of VTE risk factors have been conducted within White-American and -European populations. However, compared to Whites, Black-Americans appear to have a higher risk and incidence of VTE. Two single nucleotide polymorphisms (DNA sequence variations), factor V Leiden (G1691A) and prothrombin (G20210A), have been identified as risk factors for DVT and PE in Europeans and White-Americans, but not Black- Americans.
"VTE appears to be more common in Blacks than Whites, but while we have identified many inherited causes for VTE in Whites, no such inherited causes in Blacks have been identified," said lead researcher Prof. John Heit, of the Mayo Clinic College of Medicine, Minnesota, USA. "We wondered whether Blacks were more likely to have VTE related to common exposures that can cause VTE, such as major surgery, hospitalization for acute medical illness, trauma, fracture, or birth control pills, to account for VTE being more common in Blacks, but this does not appear to be the case. Thus, we now question whether Blacks may have some as yet unidentified inherited cause for VTE."
The researchers found that, compared to Whites with VTE, Blacks with VTE have a higher proportion of PE events, a lower proportion of VTE related to transient risk factors and a higher proportion with idiopathic VTE, i.e. from a seemingly unknown or unrelated cause.
Blacks had a significantly higher mean BMI, and a significantly lower proportion with recent surgery, trauma or infection, family history of VTE and documented thrombophilia. Conversely, Blacks had a significantly higher proportion with hypertension, diabetes mellitus, chronic renal disease and dialysis, HIV and sickle cell disease. Compared to White women, Black women had a significantly lower proportion with recent oral contraceptive use or hormone therapy
"Given the poor survival after PE, our finding of an increased prevalence of PE among Blacks (particularly idiopathic PE) is disturbing, especially when coupled with previous reports of increased complications after VTE and higher PE case-fatality among Blacks," added Heit.
The study is accompanied by an editorial by Dr. Samuel Goldhaber of Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
Full citation:
JA Heit et al; Comparison of Characteristics from White- and Black-Americans with Venous Thromboembolism: A Cross Sectional Study; American Journal of Hematology, 2010; DOI: 10.1002/ajh.21735
About the author:
John A. Heit, M.D., FACP, FACC, is Director of Coagulation Laboratories and Professor of Medicine at the Mayo Clinic College of Medicine, MN, USA.
Source:
Amy Molnar
Wiley-Blackwell
воскресенье, 26 июня 2011 г.
New Clinical Study Shows RyMed InVision-Plus® IV Connector Dramatically Reduced Catheter-Related Bloodstream Infections By Over 92%
Georgia Health Sciences University, Augusta, GA exhibited a poster at the recent 11th National Conference on Cancer Nursing Research in Los Angeles, in which their clinical study showed RyMed Technologies' zero displacement InVision-Plus® IV Connector significantly decreased the incidence of catheter-related bloodstream infections (CR-BSIs) by 92.6% on average when compared to a simple split septum with negative displacement IV connector (Becton-Dickinson Q-Syte®) and a reversed split-septum device with negative displacement IV connector (ICU Medical Clave®). No clinical studies have been published comparing different types of connectors in oncology patients on CR-BSIs. CR-BSIs can cause treatment delays, add time to nursing care, increase costs, increase mortality and decrease quality of life for the patient and family.
The purpose of the study was to determine infection rates for a split septum valve, a negative reversed split-septum valve and an intraluminal protection device (IPD) with zero displacement in both critical care and medical in-patient oncology patients.
Detailed results:
-- CR-BSI incidences decreased 96.3%, from 2.9 to 0.1 infections per 1,000 catheter days, when the RyMed InVision-Plus® needleless IV connector was used compared to the Becton-Dickinson's Q-Syte® product.
-- CR-BSI incidences decreased 88.9%, from 3.7 to 0.4 infections per 1,000 catheter days, when the RyMed InVision-Plus® needleless IV connector was used compared to the ICU Medical Clave® product.
-- Overall, 92.6% decrease in infection rate was found when using the RyMed InVision-Plus® with Neutral Advantage™ technology.
Leading the study was Dr. Cynthia C. Chernecky PhD, RN, AOCN, FAAN, Jennifer Waller, PhD both from Georgia Health Sciences University; and Denise Macklin, BSN, RNC.
Dr. Chernecky stated, "Decreasing infections is essential to quality nursing care in oncology. The use of best product when added to other nursing interventions is essential as it can enable best outcomes for treatments and ultimately quality of life and a decrease in mortality".
"This new clinical data continues to demonstrate the superior design features of RyMed's InVision-Plus® needleless IV connector technology and how they have a significant positive patient safety impact among the cancer patient population," said Dana Wm. Ryan, President & CEO, RyMed Technologies, Inc.
This poster presentation by Dr. Chernecky was preceded by another in which she highlighted similar success by the RyMed product in decreasing intraluminal thrombotic occlusions compared to a negative displacement mechanical valve. Additionally, Chernecky also delivered a podium presentation discussing new data on the apparent ineffectiveness of other silver coated needleless IV connectors.
Catheter-related bloodstream infection (CR-BSI) continues to be one of the most frequent hospital acquired infections (HAIs) reported by hospitals nationwide. It has been reported that a patient that develops a CR-BSI could die up to 25% of the time, and the industry is discovering that RyMed's InVision-Plus® technology with zero fluid displacement is going to save many lives.
Source: RyMed Technologies, Inc
The purpose of the study was to determine infection rates for a split septum valve, a negative reversed split-septum valve and an intraluminal protection device (IPD) with zero displacement in both critical care and medical in-patient oncology patients.
Detailed results:
-- CR-BSI incidences decreased 96.3%, from 2.9 to 0.1 infections per 1,000 catheter days, when the RyMed InVision-Plus® needleless IV connector was used compared to the Becton-Dickinson's Q-Syte® product.
-- CR-BSI incidences decreased 88.9%, from 3.7 to 0.4 infections per 1,000 catheter days, when the RyMed InVision-Plus® needleless IV connector was used compared to the ICU Medical Clave® product.
-- Overall, 92.6% decrease in infection rate was found when using the RyMed InVision-Plus® with Neutral Advantage™ technology.
Leading the study was Dr. Cynthia C. Chernecky PhD, RN, AOCN, FAAN, Jennifer Waller, PhD both from Georgia Health Sciences University; and Denise Macklin, BSN, RNC.
Dr. Chernecky stated, "Decreasing infections is essential to quality nursing care in oncology. The use of best product when added to other nursing interventions is essential as it can enable best outcomes for treatments and ultimately quality of life and a decrease in mortality".
"This new clinical data continues to demonstrate the superior design features of RyMed's InVision-Plus® needleless IV connector technology and how they have a significant positive patient safety impact among the cancer patient population," said Dana Wm. Ryan, President & CEO, RyMed Technologies, Inc.
This poster presentation by Dr. Chernecky was preceded by another in which she highlighted similar success by the RyMed product in decreasing intraluminal thrombotic occlusions compared to a negative displacement mechanical valve. Additionally, Chernecky also delivered a podium presentation discussing new data on the apparent ineffectiveness of other silver coated needleless IV connectors.
Catheter-related bloodstream infection (CR-BSI) continues to be one of the most frequent hospital acquired infections (HAIs) reported by hospitals nationwide. It has been reported that a patient that develops a CR-BSI could die up to 25% of the time, and the industry is discovering that RyMed's InVision-Plus® technology with zero fluid displacement is going to save many lives.
Source: RyMed Technologies, Inc
Подписаться на:
Сообщения (Atom)